Together with the other genes that were exclusively mutated in the low-quality neoantigens/low CD8+ T cell group, these findings point to the set of genetic determinants that should support the prospective exclusion of patients with GBM from the high-quality neoantigens/high CD8+ T lymphocytes group. Here, CD8A is linked to glioblastoma.